Purkinje cell loss in experimental autoimmune encephalomyelitis by MacKenzie-Graham, Allan et al.
Purkinje Cell Loss in Experimental Autoimmune
Encephalomyelitis
Allan MacKenzie-Graham1,*, Seema K. Tiwari-Woodruff2,*, Gaurav Sharma2, Cynthia
Aguilar1, Kieumai T. Vo1, Lauren V. Strickland1, Laurie Morales2, Boma Fubara3, Melanie
Martin4, Russell E Jacobs5, G. Allan Johnson3, Arthur W. Toga1, and Rhonda R. Voskuhl2
1Laboratory of Neuro Imaging, Department of Neurology, University of California, Los Angeles.
2Multiple Sclerosis Program, Department of Neurology, University of California, Los Angeles.
3Center for In Vivo Microscopy, Duke University.
4Department of Physics, University of Winnipeg.
5Beckman Institute, California Institute of Technology.
Abstract
Gray matter atrophy observed by brain MRI is an important correlate to clinical disability and disease
duration in multiple sclerosis. The objective of this study was to link brain atrophy visualized by
neuroimaging to its underlying neuropathology using the MS model, experimental autoimmune
encephalomyelitis (EAE). Volumetric changes in brains of EAE mice, as well as matched healthy
normal controls, were quantified by collecting post-mortem high-resolution T2-weighted magnetic
resonance microscopy and actively-stained magnetic resonance histology images. Anatomical
delineations demonstrated a significant decrease in the volume of the whole cerebellum, cerebellar
cortex, and molecular layer of the cerebellar cortex in EAE as compared to normal controls. The pro-
apoptotic marker caspase-3 was detected in Purkinje cells and a significant decrease in Purkinje cell
number was found in EAE. Cross modality and temporal correlations revealed a significant
association between Purkinje cell loss on neuropathology and atrophy of the molecular layer of the
cerebellar cortex by neuroimaging. These results demonstrate the power of using combined
population atlasing and neuropathology approaches to discern novel insights underlying gray matter
atrophy in animal models of neurodegenerative disease.
Keywords
cerebellum; gray matter atrophy; mouse; MRI; multiple sclerosis
Introduction
Gray matter atrophy is a common feature of many neurodegenerative diseases, including
Alzheimer’s disease (AD), Parkinson’s disease (PD), and multiple sclerosis (MS). Atrophy
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has been linked to disability in all of these diseases (Camicioli et al., 2003; Chard et al.,
2002; Firbank et al., 2007), underscoring its importance and the need to understand the
mechanisms that drive it.
Multiple sclerosis has traditionally been viewed as an inflammatory, demyelinating disease of
the central nervous system (CNS). Most patients begin with a relapsing-remitting form of the
disease, characterized by inflammation and demyelination, which gradually transitions over
several years to a secondary progressive form, characterized by progressive disability and
tissue degeneration. A growing body of literature has documented the neurodegenerative aspect
of MS (Evangelou et al., 2000; Peterson et al., 2001; Trapp et al., 1999). Whole brain atrophy
was initially described in MS (Rudick et al., 1999) and several studies have since demonstrated
a strong relationship between gray matter atrophy and disability (Ge et al., 2000; Rudick et al.,
1999; Stevenson et al., 2000), including infratentorial and cerebellar atrophy (Edwards et al.,
1999; Iannucci et al., 1999; Liu et al., 1999). Indeed, gray matter atrophy is now considered to
be one of the most clinically relevant markers of MS disease progression (Fisher et al., 2002).
The primary function of the cerebellum is the modulation of movement; it plays a crucial role
in coordination and balance. Clinical MS studies have found that fully one third of subjects
have functionally relevant cerebellar deficits (Alusi et al., 2001; Weinshenker et al., 1996) and
have demonstrated up to 19% decreases in cerebellar volume in MS patients (Edwards et al.,
1999; Liu et al., 1999). Also, cerebellar atrophy in MS is closely correlated with disability on
cerebellar functional subscales (Edwards et al., 1999; Liu et al., 1999). Thus, while cerebellar
atrophy in MS has clinically relevant consequences, its underlying etiology remains poorly
understood.
We have previously demonstrated gray matter atrophy in the cerebella of mice with
experimental autoimmune encephalomyelitis (EAE), the most widely used model of MS, and
found a correlation between this atrophy and disease duration (MacKenzie-Graham et al.,
2006). Here, we have used neuroimaging to localize cerebellar atrophy within the cortical
molecular layer and neuropathology to determine that Purkinje cell loss correlates with this
atrophy. We examine the cellular etiology of the gray matter atrophy visualized by magnetic
resonance imaging (MRI) and report that Purkinje cell loss is associated with it.
Materials and Methods
Mice
Female C57BL/6 mice, 8–12 weeks old, were purchased from the Jackson Laboratory. All
studies were performed in accordance with approval from the UCLA Office of Protection of
Research Subjects.
Antigen
Myelin oligodendrocyte glycoprotein (MOG) peptide 35–55 was purchased at greater than
98% purity (Chiron Mimotopes, Emeryville, CA).
EAE
Mice were immunized with MOG peptide 35–55 (300 µg/mouse) and Mycobacterium
tuberculosis (500 µg/mouse) emulsified in Complete Freund’s Adjuvant subcutaneously, in a
volume of 0.1 ml/mouse over two sites: the right draining inguinal and axillary lymph nodes.
One week later a booster immunization was delivered subcutaneously, over the contralateral
draining lymph nodes. Pertussis toxin (500 ng/mouse) (List Biological Laboratories, Inc.,
Campbell, CA) was injected intraperitoneally on days 0 and 2 (Liu et al., 2003; Suen et al.,
1997). EAE was graded on a scale of 0 to 5, based on difficulty with ambulation, as described
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(Pettinelli and McFarlin, 1981). A total of five independent EAE groups were used in this
study, extending from day 15 to day 147 after disease induction.
Magnetic Resonance Microscopy
Mice were perfused intracardially and post-fixed with 4% paraformaldehyde (Sigma-Aldrich,
St. Louis, MO). After post-fixation the brains were incubated in PBS for 10–15 days prior to
imaging. Magnetic resonance microscopy (MRM) was performed using an 89 mm vertical
bore 11.7 T Bruker Avance imaging spectrometer with a micro-imaging gradient insert with a
maximum gradient strength of 100 G/cm and 30 mm birdcage RF coil (Bruker Instruments,
Billerica, MA). The brains were held in custom-made delrin holders in test tubes filled with
Fomblin Perfluoropolyether (PFPE) YO4 grade (Ausimont USA, Inc., Thorofare, NJ) and
maintained at 4°C. Typical imaging parameters were as follows: T2-weighted RARE 3D
imaging protocol (8 echoes), matrix dimensions = 256 × 256 × 256; FOV = 3 cm × 1.5 cm ×
1.5 cm; repetition time (TR) = 1500 ms; effective time (TE) = 10 ms; number of averages = 4.
The images were padded with zeros to double the number of time domain points in each
dimension, the Fourier transformed to yield a matrix of 512 × 256 × 256. This procedure is
commonly called “zero-filling” and is a well known interpolation method (Farrar and Becker,
1971; Fukushima and Roeder, 1981). Typical spatial resolution was approximately 60 µm3 per
voxel.
Magnetic Resonance Histology
All magnetic resonance histology (MRH) (Johnson et al., 1993) was performed at the Duke
Center for In Vivo Microscopy (CIVM), an NCRR/NCI National Resource. Specimens were
actively stained for MR histology using a mixture of formalin and Prohance (Bracco, Princeton,
NJ) to reduce the spin lattice relaxation time (T1) (Johnson et al., 2002a; Johnson et al.,
2002b). Staining employed a multi-step transcardial perfusion in which pressure, temperature,
and perfusate composition are carefully controlled to optimize the penetration of fixative and
gadolinium contrast agent. Upon completion of the perfusion the head was removed and placed
in a cylindrical acrylic container filled with perflourocarbon to limit susceptibility effects. The
brain was scanned in the skull to limit physical distortion. This preparation permitted us to
collect serial sections from the tissue after scanning.
All scanning was done at 9.4 T in a 12 mm diameter solenoid coil. Data were acquired with
an RF refocused spin echo sequence. The sequence employs a sampling strategy in which
Fourier space is sampled asymmetrically with 384 × 384 × 768 points. The strategy samples
one side of Fourier space (along all three axes) at the Nyquist frequency sufficient to support
21.5 micron spatial resolution. The unsampled points on the opposite side of Fourier space are
zero filled. The dynamic range of the receiver is increased in the periphery of Fourier space to
preferentially weight the higher frequencies resulting in a simultaneous reduction of scan time
while maintaining the high spatial resolution. Data are displayed as magnitude images on a
512 × 512 × 1024 array with effective isotropic spatial resolution of 21.5 microns. Scan time
is 2.05 hrs.
Image Processing
MRM and MRH images were skull-stripped using the Brain Surface Extractor (BSE) within
BrainSuite 2 (Shattuck and Leahy, 2001). Inaccuracies were corrected by manually editing the
masks using BrainSuite 2. After skull-stripping, field inhomogeneities were corrected using
N3 correction (Sled et al., 1998). A minimum deformation target (MDT) was produced as
described (Kochunov et al., 2001). Each of the images was then linearly aligned to the MDT
with a 12-parameter full-affine transformation using Alignlinear (AIR 5.2.5) (Woods et al.,
1998a; Woods et al., 1998b) and the least squares with intensity rescaling cost function
followed by a 5th-order polynomial warp using Align_warp (AIR). The images were then
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resampled and averaged to produce the final minimum deformation atlas (MDA). The MDA
was then aligned to a standard atlas (MacKenzie-Graham et al., 2004) to permit the direct
comparison of images in a standard space. All automated image processing was performed in
the LONI Pipeline Processing Environment (Rex et al., 2003) using either a 32-processor Onyx
200 or 64-processor Origin 3000 supercomputer (SGI).
Anatomical Delineations
A blinded expert neuroanatomist using BrainSuite 2 manually delineated anatomical structures
on the MDA. Cerebellar delineations included cerebellar cortex, the molecular layer of the
cerebellar cortex, and cerebellar white matter. Cerebellar cortex delineations rigorously
excluded white matter and partial volume voxels. Molecular layer of the cerebellar cortex
delineations were made taking advantage of the contrast between the molecular layer of the
cerebellar cortex and the granule cell layer provided by the active stained MRH scans.
Anatomical delineations were based on the Mouse Atlas Project 2003 mouse brain atlas
(MacKenzie-Graham et al., 2004).
Image Analysis
Images were spatially normalized with a 12-parameter full-affine transformation to register
each image to the MDA using Alignlinear (AIR). In order to intensity normalize the images
the alignment was performed with an intensity rescaling cost function. Align_warp (AIR) was
used to compute 5th-order polynomial mappings of the MDA to each individual normalized
brain. These mappings were then used to warp the anatomical delineations from the MDA to
each of the individual images. Individual delineations were then manually corrected in
BrainSuite 2.
Immunohistochemistry
After magnetic resonance histology (MRH), brains were removed from the skull and prepared
for sectioning. 50 μm sagittal frozen sections were cut using a CM3050S cryostat (Leica
Microsystems, Wetzlar, Germany). Free-floating sections were permeabilized in 0.3% Triton
X-100 in PBS and blocked with 10% normal goat serum (Vector Laboratories, Burlingame,
CA). White matter immunostaining was enhanced by treating sections with 95% ethanol/5%
acetic acid for 15 minutes prior to permeabilization and blocking. Specific cell types and
structures, sections were pre-incubated with primary antibodies in PBS solution containing 2%
NGS for 2 hours at room temperature, then overnight at 4°C. The following primary antibodies
were used: rabbit anti-parvalbumin (1:1000) (Millipore, Billerica, MA), rat anti-myelin basic
protein (1:500) (Millipore), rat anti-CD45 (1:1000) (Millipore), mouse anti-NeuN (1:500)
(Millipore), rabbit or mouse anti-caspase-3 (1:250) (Millipore), rabbit anti-synapsin (1:500)
(Millipore), rabbit anti-neurofilament-NF200 (1:1000) (Sigma-Aldrich), mouse or rabbit anti-
calbindin-2 (1:750)(Sigma-Aldrich). Fluorescence secondary antibody labeling included
antibodies conjugated to TRITC, FITC, and Cy5 (Vector Laboratories and Millipore).
Chromogen immunohistochemistry was performed, after avidin-biotin block, by incubating
with mouse anti-caspase-3 (Millipore) alone or sequentially with rabbit anti-calbindin-2
(Sigma-Aldrich) followed by biotinylated secondary antibody. A streptavidin-peroxidase
conjugate was added, followed by the addition of the chromogen (blue/gray or red; Vector
Laboratories). The sections were mounted, dehydrated and coverslipped with Permount (Fisher
Scientific, Pittsburgh, PA). IgG-control experiments were performed for all primary
antibodies, and no staining was observed under these conditions. To assess the number of cells,
4',6'-diamidino-2-phenylindole dihydrochloride (DAPI 2ng/ml; Invitrogen, Carlsbad, CA) was
added for 15 minutes prior to final washes after secondary antibody addition. The sections were
mounted on slides, dried, and coverslipped with fluoromount G (Fisher Scientific). Both mouse
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and rabbit anti-caspase-3 and anti-calbindin-2 antibodies were used to permit different staining
combinations. Staining was comparable between mono- and polyclonal antibodies.
Microscopy and Analysis
Confocal images of immunostained sections were photographed using a spin-disc (Olympus,
Center Valley, PA) and TCS-SP laser confocal microscope (Leica Microsystems) with a digital
camera (Hamamatsu Photonics, Bridgewater, NJ). All images were collected using similar
acquisition parameters. Photomicrographs of each representative experimental group were
collected and analyzed with ImageJ software (v1.36b).
The degree of demyelination and inflammation in cerebellar white and gray matter was
assessed by quantifying anti-MBP and anti-CD45 staining by optical density. Confocal stacks
of immunolabeled images from each animal were processed with a series of manual and
automated procedures that included the following steps: (1) the images were oriented in the
same direction, (2) the RGB channels of the images were split and converted to 8 bit gray
images in Image J, (3) gray matter (granule cell, Purkinje cell and molecular layer) and white
matter was manually delineated on the basis of DAPI staining, and (4) threshold gray matter
and white matter density was calculated and reported as a percentage of total area.
Synapsin staining density in the molecular layer of the cerebellar cortex was assessed by
quantifying anti-synapsin staining by optical density. Confocal stacks of immunolabeled
images from each animal were processed with a series of manual and automated procedures
that included the following steps: (1) the images were oriented in the same direction, (2) the
RGB channels of the images were split and converted to 8 bit gray images in Image J, (3) the
molecular layer was manually delineated on the basis of DAPI staining, and (4) threshold
synapsin staining density was calculated and reported as a percentage of total area.
Cell Counts
Purkinje cells were quantified by counting calbindin-2+ cell bodies in the Purkinje layer of 4X
and 10X images of the entire cerebellum. Fluorescence-stained sections were counted using
z-stacks with at least 15–20 optical sections 2 µm apart. Every third optical section was
analyzed and averaged. Dehydration in chromogen-stained sections does not permit many z-
planes to be available, so here we counted Purkinje cells in a projected image. Results from
the chromogen-stained sections were similar to fluorescent sections. Three to five brain
sections (50 µm thick) 200 µm apart were analyzed from each animal (control: n = 5; EAE: n
= 7). All sections counted were close to midline. In every analysis, the same areas from EAE
and normal mice were assessed. Only cells with their entire nucleus present in the section were
counted. Some animals were excluded from the analysis due to incomplete perfusion or because
the tissue was damaged. Blinded cell counting was performed using lobules I/II and III to
estimate and compare the total number of Purkinje cells. These lobules were chosen since
lobules I/II and III were consistently present in all tissue sections, whereas other lobules were
missing from some preparations and thus could not be used for comparisons among all the
mice. Additional cell counts were performed on a subset of tissue sections where the entire
cerebellum was present. While the total number of sections where the entire cerebellum was
intact was reduced, these counts showed a similar pattern when comparing EAE mice and
controls as that observed when lobules I/II and III were examined (data not shown).
Furthermore, another set of sections was examined in which lobules IV, IX and X were intact
and again the same pattern was observed as in lobules I/II and III (data not shown).
Statistics
All results are presented as mean ± SEM, and statistical differences were determined by the
Welch’s t-test. Regression analysis and Welch’s t-tests were performed in Excel (Microsoft).
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Comparisons across EAE time points were subject to post hoc multiple comparisons
confounds, so the results of the Bonferroni correction (p < α/n) were considered.
Results
MOG-induced EAE in C57BL/6 has a chronic progressive disease course. The literature
focuses primarily on disease in the spinal cord, but inflammation and focal lesions have been
demonstrated in the cerebellum and forebrain as well (Black et al., 2006; Carter et al., 2007;
Kuerten et al., 2007; Lees et al., 2008; MacKenzie-Graham et al., 2006; Melzer et al., 2008;
Selvaraj and Geiger, 2008; Uemura et al., 2008). Mice with this form of EAE develop focal
lesions that are easily identifiable by T2-hyperintensities in the cerebellar white matter, brain
stem, and spinal cords. These lesions are readily detected at day 15 after disease induction (Fig.
1A). We were able to confirm that the T2-hyperintensities in the MRM images were white
matter lesions by histology, using a reducing silver myelin stain combined with Nissl-staining
for cell bodies. Indeed, our C57BL/6J mice with MOG 35–55 induced active EAE
demonstrated significant focal lesions in the cerebellar white matter (Figs. 1B & C), brainstem,
and spinal cord (day 55). Here we will focus on the remote effects of white matter lesions on
gray matter using neuroimaging and neuropathology.
An MRM Atlas of EAE Brain
In order to address the issue of gray matter atrophy in mice with EAE, we acquired post-mortem
T2-weighted magnetic resonance microscopy (MRM) scans from two independent EAE
groups totaling 32 mice. The active induction model of EAE in the C57BL/6 mouse with myelin
oligodendrocyte glycoprotein (MOG) was used. This model is characterized by disease onset
at 12–14 days post-induction followed by chronic disability. 5 mice were sacrificed early in
disease (day 15), 8 mice in the middle stages of disease (day 35–47), 8 mice late in disease
(day 48–57) and scanned. 11 strain-, age-, and sex-matched healthy controls were also
sacrificed and scanned. All the scans were skull-stripped semi-automatically and corrected for
field inhomogeneity.
A minimum deformation atlas (MDA) was constructed from the 32 MRM scans collected. The
MDA was then aligned to a standard atlas (MacKenzie-Graham et al., 2004) to permit the direct
volumetric comparison of images in a standard space. The standard minimum deformation
atlas then served as a target space for the spatial and intensity normalization of the original
images, correcting both gross size differences and gross intensity differences. Following
creation of this atlas, anatomical structures (e.g. whole cerebellum, cerebellar cortex, cerebellar
white matter) were manually delineated on that atlas (Fig. 2). The delineations were then
warped onto the images that were used to create the atlas to produce standardized estimates of
regional atrophy in individual subjects.
Atrophy in the Cerebella of Mice with Late EAE
Mice with EAE demonstrate motor deficits that may reflect damage to corticospinal and/or
spinocerebellar tracts. MOG-induced EAE is known to induce spinal cord and cerebellar white
matter lesions, so we hypothesized that atrophy of the cerebellum might occur as a remote
effect of transection of spinocerebellar or other cerebellar white matter tracts. We found a
significant reduction in cerebellar volume in mice with late EAE compared to normal controls.
The volume of the cerebellum in normal mice had mean of 48.2 ± 0.3 mm3. Mice in the late
stages of EAE had a mean cerebellar volume of 45.0 ± 0.7 mm3. This reflected a 6.6% decrease
in cerebellar volume (p = 0.0036).
Brain atrophy has been shown to correlate with disease duration in MS (Ge et al., 2000; Kalkers
et al., 2001), so we examined the relationship between cerebellar volume and disease duration
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in mice with EAE. We performed a regression analysis to determine if disease duration
correlated with cerebellar volume in mice with EAE. There was an inverse correlation between
cerebellar volume and disease duration, indicating that atrophy occurs progressively during
disease as a function of time (Figs. 3A & B) (R = −0.6178, n = 21, p = 0.0028). The disease
course for this cohort of mice is overlaid on the graph for illustrative purposes (Fig. 3B).
No Significant Atrophy in the Cerebellar White Matter of Mice with EAE
Lesions are known to occur in cerebellar white matter tracts in EAE and it was possible that
some of the atrophy detected in whole cerebellum was occurring in the white matter tracts. We
measured the volumes of the cerebellar white matter in mice with MOG-induced EAE and
normal controls. The volume of the cerebellar white matter in normal mice had mean of 6.60
± 0.14 mm3. Mice in the late stages of EAE had a mean cerebellar white matter volume of 6.28
± 0.22 mm3. This decrease in cerebellar white matter volume did not reach statistical
significance (p = 0.12). We performed a regression analysis to determine if disease duration
correlated with cerebellar white matter volume in mice with EAE. There was no correlation
between disease duration and cerebellar white matter volume (Figs. 3C & D) (R = −0.0747, n
= 21, p = 0.75). The disease course for this cohort of mice is overlaid on the graph for illustrative
purposes (Fig. 3D).
Atrophy in the Cerebellar Cortex of Mice with late EAE
In order to assess whether the atrophy discovered in whole cerebellum was occurring primarily
in the gray matter, we measured the volumes of the cerebellar cortex in mice with EAE and
normal controls. We found a significant reduction in cerebellar cortex volume in mice with
late EAE compared to normal controls. The volume of the cerebellar cortex in normal mice
had mean of 39.7 ± 0.3 mm3. Mice in the late stages of EAE had a mean cerebellar cortex
volume of 36.9 ± 0.8 mm3. This reflected a 7.2% decrease in cerebellar cortex volume (p =
0.0047). We performed a regression analysis to determine if disease duration correlated with
cerebellar cortex volume in mice with EAE. There was an inverse correlation between
cerebellar cortex volume and disease duration, indicating that cerebellar cortex atrophy occurs
progressively during disease as a function of time (Figs. 3E & F) (R = −0.6207, n = 21, p =
0.0027). The disease course for this cohort of mice is overlaid on the graph for illustrative
purposes (Fig. 3F).
An MRH Atlas of EAE Brain
In order to further localize the gray matter atrophy in the cerebellum, we acquired post-mortem
MRH scans from two additional independent EAE groups totaling 21 mice. Differences in the
contrast between the MRH and MRM scans allowed us to unambiguously delineate the
molecular layer of the cerebellar cortex (Fig. 2 B & C). We had appreciated from the initial
experiments that atrophy was progressing as a function of time, thus we chose later time points
to increase our chances of being able to localize the precise gray matter layer in the cerebellum
that was undergoing atrophy. 10 mice very late in disease (day 61–147) and 11 strain, age, and
sex matched healthy controls were also sacrificed and imaged. All the scans were skull-stripped
semi-automatically and corrected for field inhomogeneity.
A minimum deformation atlas was constructed from the 21 MRH scans collected. The MDA
was then aligned to a standard atlas (MacKenzie-Graham et al., 2004) to permit the direct
volumetric comparison of images in a standard space. The standard minimum deformation
atlas then served as a target space for the spatial and intensity normalization of the original
images, correcting both gross size and intensity differences. Following creation of this atlas,
anatomical structures were manually delineated on that atlas and then warped onto the images
that were used to create the atlas to produce standardized estimates of regional gray matter loss
in individual subjects. Though the MRH scans were acquired on a different scanner using a
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different protocol than the MRM scans, alignment of the images to a standard space allowed
direct volumetric comparison of MRM and MRH images. We used the MRH images to further
localize the region in which gray matter atrophy was occurring.
Atrophy in the Molecular Layer of the Cerebellar Cortex of Mice with EAE
In this second independent experiment, we again found atrophy in the whole cerebellum and
in addition found atrophy in the molecular layer of the cerebellar cortex in mice with late EAE
compared to normal controls. The volume of the whole cerebellum in normal mice had a mean
of 48.3 ± 0.3 mm3. Mice in the late stages of EAE had a mean whole cerebellar volume of 46.1
± 0.4 mm3. This reflected a 4.6% decrease in cerebellar volume (p = 0.05). The volume of the
molecular layer of the cerebellar cortex in normal mice had mean of 30.5 ± 0.6 mm3. Mice in
the late stages of EAE had a mean molecular layer of the cerebellar cortex volume of 28.2 ±
0.6 mm3. This reflected a 7.3% decrease in molecular layer of the cerebellar cortex volume (p
= 0.0086). We performed a regression analysis to determine if disease duration correlated with
volume of the molecular layer of the cerebellar cortex in mice with EAE. There was an inverse
correlation between the volume of the molecular layer of the cerebellum and disease duration,
indicating that cerebellar cortical atrophy in the molecular layer occurs progressively during
disease as a function of time (Figs. 3G & H) (R = −0.6562, n = 10, p = 0.039). The disease
course for this cohort of mice is overlaid on the graph for illustrative purposes (Fig. 3H).
No Atrophy in a Control Region in Mice with EAE
To determine whether the atrophy observed in cerebellar gray matter during late EAE
represented some generalized phenomenon related to chronic disease (dehydration, etc.), as
opposed to reflecting regionally specific gray matter atrophy, we measured the volumes of an
area unlikely to be greatly affected by EAE, the olfactory area, as a negative control.
Measurements of the volumes of the olfactory area from both MRM and MRH imaged mice
were then subjected to the same statistical and regression analysis. There was no significant
difference in olfactory area volume between mice with EAE and normal controls and the
correlation observed during analysis of cerebellar cortex was not observed in this control region
(data not shown). These data indicate that cerebellar gray matter atrophy in the molecular layer
during late EAE was regionally specific.
Demyelination in the Cerebella of Mice with EAE
Once we had established that the largest part of the gray matter atrophy that we observed was
in the molecular layer of the cerebellar cortex, we looked for pathological correlates in tissue
collected from the mice that had been MRH imaged. As expected, we observed demyelination
in the cerebellar white matter of mice with EAE (Fig. 4D). At higher magnification, we were
able to identify lesions that were not only demyelinated, but were devoid of axons (Fig. 4E).
Furthermore, we observed areas of demyelination in the granule cell layer of the cerebellar
cortex and the presence of swollen axons and/or axon retraction bulbs (Fig. 4F) similar to those
described previously in the brains of MS patients (Trapp et al., 1998). Demyelination was
absent from normal age, sex, and strain matched controls (Figs. 4A–C). Upon quantification,
we found a significant difference in the myelin basic protein (MBP) staining density in the
cerebella of mice with EAE compared to normal controls (p < 0.00005).
Regression analysis demonstrated that MBP staining density in the cerebellar white matter had
a direct correlation with the volume of the molecular layer of the cerebellar cortex (R = 0.6132,
n = 12, p = 0.03398) (Fig. 4G). Similarly, a regression analysis demonstrated that MBP staining
density in the cerebellar cortex had a direct correlation with the volume of the molecular layer
of the cerebellar cortex (R = 0.8069, n = 12, p = 0.001514) (Fig. 4H). These data indicate that
demyelination is associated with gray matter atrophy in the cerebella of mice with MOG-
induced EAE.
MacKenzie-Graham et al. Page 8













Inflammation in the Cerebella of Mice with EAE
As expected, we observed extensive inflammatory cellular staining in the cerebella of mice
with EAE (Fig. 5D). At higher magnification, we were able to identify CD45+ cells with a
rounded morphology in the cerebellar white matter (Fig. 5E) and CD45+ cells with an activated
microglia-like morphology in the molecular layer of the cerebellar cortex (Fig. 5F). CD45
immunostaining in normal age, sex, and strain-matched controls identified only occasional
ramified microglia (Fig. 5A–C). Upon quantification, we found a significant difference in
CD45+ staining density in the cerebella of mice with EAE compared to normal controls (p <
0.00005).
Regression analysis demonstrated that the number of CD45+ cells in the cerebellar white matter
had an inverse correlation with the volume of the molecular layer of the cerebellar cortex (R
= −0.6942, n = 12, p = 0.01226) (Fig. 5G). Similarly, a regression analysis demonstrated that
CD45+ staining density in the cerebellar cortex had an inverse correlation with the volume of
the molecular layer of the cerebellar cortex, but this trend did not reach statistical significance
(R = −0.5345, n = 12, p = 0.07338) (Fig. 5H). These data indicate that white matter CD45+
staining density is associated with gray matter atrophy in the cerebella of mice with MOG-
induced EAE.
Characterization of CD45+ cells in the Cerebella of Mice with EAE
Although CD45 is a marker for inflammatory cells, it does not discriminate the lineage of the
cells it labels. In order to better characterize the CD45+ cells we observed in mice with EAE,
we stained with CD3 (T-cells) and Mac-3 (macrophages and activated microglia). The
CD45+ cells in the cerebella of mice with EAE comprised both CD3+ and Mac-3+ cells.
Interestingly, both CD3+ and Mac-3+ cells were present in both the cerebellar white matter
(Figs. 6A & C) and in all layers of the cerebellar cortex (Figs. 6B & D). White matter images
(Figs. 6A & C) were centered on blood vessels to demonstrate continuing cellular infiltration
even late in disease. Gray matter images (Figs. 6B & D) were focused on areas of intense
cellular infiltration to visualize cellular morphology.
Apoptosis in the Cerebellar Cortex of Mice with EAE
Gray matter inflammation, demyelination, and atrophy led us to investigate if neurons in the
cerebellar cortex were undergoing apoptotic cell death. We selected one of the most
downstream effector molecules in the apoptosis pathway, caspase-3. Using antibodies for
activated caspase-3, we observed an almost complete absence of staining from healthy controls
(Figs. 7A–C). However, we observed substantial immunostaining in the cerebella of mice with
EAE, not only in the cerebellar white matter, but also in the granule cell layer of the cerebellar
cortex, and particularly in the Purkinje layer of the cerebellar cortex (Fig. 7D). At higher
magnification, we were able to identify caspase-3+ cells with a Purkinje cell-like morphology
(Fig. 7E) in mice with EAE. Double staining with caspase-3 and calbindin-2 verified that these
cells were in fact Purkinje cells (Fig. 7F). Upon quantification, we found a significant difference
in the number of caspase-3+ Purkinje cells in the cerebella of mice with EAE compared to
normal controls (p < 0.00005). The number of the caspase-3+ Purkinje cells in normal mice
had a mean of 0.65 ± 0.033 per lobule. Mice in the late stages of EAE had a mean of 7.2 ± 1.43
per lobule. This reflected a 10-fold increase in the number of caspase-3+ Purkinje cells in EAE.
Purkinje cells also expressed terminal deoxynucleotidyl transferase dUTP nick end labeling
(TUNEL) staining in mice with EAE (data not shown).
Decreased Purkinje Cell Number in the Cerebella of Mice with EAE
We further investigated Purkinje cell pathology in the cerebella of mice with EAE. Calbindin-2
immunostaining demonstrated a disruption of the normal anatomy of the Purkinje and
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molecular layers of the cerebellar cortex compared to normal controls (Figs. 8A & C). At higher
magnification we observed an overall disorganization, changes in dendritic arborization, a
reduction in cell soma size, and a decrease in the numbers of Purkinje cells in mice with EAE
compared to normal control mice (Figs. 8B & D). Upon quantification, we found a significant
decrease in the number of calbindin-2+ cells in the cerebella of mice with EAE as compared
to normal controls. Specifically, the number of the calbindin-2+ cells in normal mice had a
mean of 113.5 ± 5.5, while mice in the late stages of EAE had a mean of 86.0 ± 6.0. This
reflected a 24.2% decrease in the number of calbindin-2+ cells (p < 0.001).
Regression analysis demonstrated that the number of calbindin-2+ cells had a direct correlation
with the volume of the molecular layer of the cerebellar cortex (R = 0.6287, n = 11, p = 0.03826)
(Fig. 8E). These data indicate that Purkinje cell loss is associated with gray matter atrophy in
the cerebella of mice with MOG-induced EAE.
It is possible that the decrease we observed in dendritic arborization could due to the
redistribution of calbindin-2 from intact dendrites to the cell body (Wang et al., 2007). In order
to address this we selected synapsin to evaluate the synaptic density of neurons in the cerebellar
cortex. Synapsin staining was decreased in mice with EAE compared to normal controls (Fig.
9). The synapsin staining density in the molecular layer of the cerebellar cortex in normal mice
had mean of 55.7 ± 1.7%. Mice in the late stages of EAE had a mean synapsin staining density
in the molecular layer of the cerebellar cortex of 15.2 ± 7.1%. This reflected a 73% decrease
in synapsin staining density in the molecular layer of the cerebellar cortex (p = 0.016). These
data are consistent with dendritic arborization loss in Purkinje cells in mice with EAE.
Time Course of Inflammatory Changes in the Cerebella of Mice with EAE
Cross modality correlation of MRI with pathology revealed several associations with atrophy:
inflammation, demyelination, and Purkinje cell loss. In order to further discern the sequence
of neuropathological events, we used a complementary approach. We had previously found
significant cerebellar cortical atrophy at day 55 of EAE, but not at day 15 or day 35
(MacKenzie-Graham et al., 2006). Therefore an additional set of 17 mice was studied to
determine the sequence of neuropathological events preceding the onset atrophy at day 55.
Mice were sacrificed at three time points during disease, days 15, 35, and 55. Strain, age, and
sex matched healthy controls were also sacrificed in parallel at each time point. We observed
extensive inflammatory cell staining in the cerebella of mice with EAE. Significant CD45
immunoreactivity was observed in the white matter of cerebellar sections beginning in EAE
mice at day 15. Upon quantification, CD45 staining in white matter peaked at day 35, and then
at day 55 returned to levels that were not significantly different from levels at day 15 in EAE
(Fig. 10A). At all time points EAE mice had significantly more CD45 white matter staining
than controls (p > 0.05).
In general, CD45 staining in gray matter was much less than in white matter. Importantly, in
contrast with white matter staining, CD45 immunoreactivity in the gray matter appeared to
increase continuously with time in EAE (Fig. 10B). Specifically, later disease time points had
greater CD45 staining than earlier time points. At all time points mice with EAE had
significantly more CD45 gray matter staining than controls (p > 0.05). Notably, a substantial
increase in white matter CD45+ staining at day 35 preceded previously documented gray matter
atrophy (MacKenzie-Graham et al., 2006) at day 55, while gray matter CD45+ staining was
highest at a time that coincided (day 55) with gray matter atrophy.
Time Course of Demyelination in the Cerebella of Mice with EAE
MBP immunoreactivity was measured to explore the state of myelination in both white and
gray matter at each time point in this set of mice dedicated to examining the time course of
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neuropathological events that precede atrophy detection by MRI. Throughout the time course,
control tissue showed dense MBP staining in the central white matter tracts, with regular,
parallel arrays of myelinated axons radiating into the granule cell layer. As expected, white
matter myelination was substantially greater than gray matter myelination. Quantification
indicated that white matter MBP immunoreactivity was significantly lower in EAE mice than
controls at all time points (p > 0.05) (Fig. 10C). Cross comparison within EAE showed that
subsequent time points had lower MBP immunoreactivity values than at day 15. Decreases in
gray matter MBP immunoreactivity occurred primarily in regions juxtaposed to white matter
lesions. However, some lesions extended directly from white matter into the granule cell layer.
Gray matter MBP immunoreactivity in EAE showed a decreasing trend that reached
significance (p > 0.05) at day 55 (Fig. 10D). Notably, white matter demyelination at day 35
preceded gray matter atrophy previously documented at day 55 (MacKenzie-Graham et al.,
2006), while gray matter demyelination reached significance coincident with gray matter
atrophy at day 55.
Time Course of Purkinje Cell Number in the Cerebella of Mice with EAE
We assessed Purkinje cell number at each time point to determine when Purkinje cell loss
occurred relative to the above sequence of inflammatory and demyelinating events. Differences
in Purkinje cell density between control and EAE mice were not observed early in disease, at
days 15 and 35 (Fig. 10E). However, EAE mice had substantially decreased neuronal density
in the Purkinje layer at day 55 as compared to age matched controls. This appeared to be due
to the loss of calbindin-2+ Purkinje cells. By day 55 substantial numbers of Purkinje cells were
absent (Fig. 8). Age matched controls did not display these characteristics at any time point.
The decrease in Purkinje cell number showed a precise temporal correlation with previously
documented gray matter atrophy measured by MRI at day 55 in EAE (MacKenzie-Graham et
al., 2006).
Discussion
MS is an inflammatory, demyelinating disease of the central nervous system (CNS) that results
in damage to myelin, oligodendrocytes, axons, and neurons. Inflammation, demyelination, and
neurodegeneration are intimately tied together (Geurts and Barkhof, 2008), and although MRI
cannot establish the mechanisms of neurodegeneration, increasingly sophisticated imaging and
analysis techniques are making it possible to determine precisely where and when it occurs.
Here we have determined that, in the most widely used model for MS, the loss of Purkinje cells
is clearly associated with gray matter atrophy in the molecular layer of the cerebellum. This is
especially relevant in light of findings in MS which demonstrated not only demyelination, but
Purkinje cell loss in the cerebellar cortex (Kutzelnigg et al., 2007).
There is a growing body of evidence that the cerebellum is targeted in several models of EAE.
Though MOG peptide induced EAE is one of the most commonly used models of EAE, many
models are used, each with subtly different disease courses and pathologies. Disruption of the
blood-brain barrier (BBB) at the cerebellum occurs early in disease in Lewis rats as visualized
using ultra small particles of iron oxide (USPIO) in MRI (Floris et al., 2004; Rausch et al.,
2003). The same has been shown in SJL/J mice with proteolipid protein (PLP) peptide 139–
151-induced EAE, where cerebellar BBB breakdown was demonstrated to occur prior to
disruption of the BBB in the spinal cord and prior to the development of clinical symptoms
(Tonra, 2002; Tonra et al., 2001). Interestingly, this work demonstrated that the rabbit
immunoglobulins used to evaluate BBB breakdown accumulated around Purkinje cells. In an
atypical model of EAE in C3H/HeJ mice immunized with PLP peptide 190–209 BBB
disruption and cellular infiltration were also shown in the cerebellum (Muller et al., 2005).
These findings are all consistent with our observations of inflammatory cell infiltration in the
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cerebellum as early as day 15. Furthermore, tumor necrosis factor (TNF)-related apoptosis-
inducing ligand (TRAIL) has also been reported to induce caspase-3 mediated cell death in the
brainstems of SJL/J mice immunized with PLP peptide 139–151 (Aktas et al., 2005),
reinforcing our finding that neuronal cell death is occurring during EAE.
In MS, if an axon is not transected by inflammatory segmental demyelination, redistribution
of sodium channels can re-establish conduction across the demyelinated segment and improve
function (Craner et al., 2004). However, this increases the energy demands of neuronal
conduction and renders the demyelinated axon more susceptible to hypoxic/ischemic damage
(Dutta et al., 2006). Furthermore, these channels do not have the same electrical characteristics
as the original ones and may be responsible for some MS symptoms. Purkinje cells are the only
output neurons of the cerebellar cortex and are critical in motor coordination, learning, and
timing (Mauk et al., 2000). There is a growing body of evidence suggesting that abnormal
expression of sodium channels may distort the pattern of Purkinje cell firing and thus contribute
to cerebellar ataxia in MS and EAE (Black et al., 2000; Craner et al., 2003; Craner et al.,
2004; Damarjian et al., 2004; Waxman, 2005). Specifically, expression of Nav1.8 (SNS) is
upregulated in expression in Purkinje cells in mice with EAE and humans with MS. This
aberrant expression was associated with altered Purkinje firing patterns, with high-frequency
sustained firing in response to prolonged depolarization, a factor that could lead to energy
deprivation in these neurons (Renganathan et al., 2003). Our finding of Purkinje cell loss in
this study is consistent with the hypothesis that abnormal channel expression can render a
neuron susceptible to cell death in EAE. In addition, we observed a disorganization and
decrease in the dendritic arborization of Purkinje cells in mice with EAE. Furthermore, our
observation of decreased synapsin staining density in the molecular layer of the cerebellar
cortex is consistent with a decrease in Purkinje cell dendritic arborization and with the literature
describing decreases in synapsin expression in the spinal cords of mice with EAE (Nicot et al.,
2005) and decreases in dendritic spine density and arbors, along with atrophy of the cell body
and/or complete cell loss (Bannerman et al., 2005).
Cerebellar atrophy in MS is closely correlated with disability on cerebellar functional subscales
(Edwards et al., 1999; Liu et al., 1999), however it has often been attributed to tract
degeneration. In the murine cerebellum, white matter tracts contribute only 14% of the volume,
and though there was a trend toward some white matter atrophy in mice with EAE, this change
in cerebellar white matter volume did not account for the majority of the reduction in cerebellar
volume in mice with EAE. Cerebellar cortex volume loss, not white matter volume loss,
accounted for the majority of the cerebellar atrophy we observed. However, we cannot rule
out gray matter atrophy in other cerebellar structures, such as the deep cerebellar nuclei or the
granule cell layer of the cerebellar cortex.
At very late time points (day 61–147), we found that cortical atrophy correlated with white
matter inflammation (Fig. 5). Further data collected, from a different cohort of EAE mice,
indicated that the level of white matter inflammation at the late time points was less than the
level of white matter inflammation at day 35 (Fig. 10). Notably, higher levels of white matter
inflammation relatively early in disease (day 35) do not preclude the possibility that low levels
of chronic white matter inflammation late in disease could correlate with gray matter atrophy.
Interestingly, our data show that high levels of inflammation in white matter at day 35 do not
correlate with concurrent gray matter atrophy at this earlier time point, since very little gray
matter atrophy was observed at day 35 (MacKenzie-Graham et al., 2006). This could be due
to a variety of reasons. For example, white matter inflammation may require time to induce
neurodegenerative changes in remote gray matter regions. Indeed, in contrast to late time
points, we have not seen caspase-3+ or TUNEL+ Purkinje cells in the cerebella of mice with
EAE at relatively early time points (day 15–47; unpublished observations). This is consistent
with Purkinje cell death occurring only when cerebellar atrophy is measurable.
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In summary, we have demonstrated for the first time that atrophy of a gray matter structure
which occurs during autoimmune mediated demyelination is associated with histopathological
evidence of widespread caspase-3 mediated cell death of a major neuronal cell type within this
structure. Understanding relationships such as these will permit the future design of rational
neuroprotective strategies to prevent gray matter atrophy and disability accumulation during
EAE, and possibly MS. Finally, cross-modality correlations between imaging and pathologic
data, as described herein, may be a useful approach in a variety of neurodegenerative disease
models.
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Fig. 1. White Matter Lesions in EAE
A, Postmortem high-resolution T2-weighted magnetic resonance microscopy image of a
C57BL/6 mouse with myelin oligodendrocyte glycoprotein-induced active experimental
autoimmune encephalomyelitis (EAE). Cerebellar white matter lesions are clearly visible as
T2 hyperintensities (arrowheads) in the early stages of disease (day 15). B, A 2X magnification
image of a serial section though the cerebellum of a mouse with EAE (day 55) stained with a
reducing silver myelin stain and counterstained with thionin (Nissl). The focal lesions are
clearly visible as disruptions in the cerebellar white matter (stained light brown). C, A 10X
magnification image of the inset in panel B demonstrating a typical lesion.
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Fig. 2. Mouse Brain Imaging
A, A diffusion weighted image of a 100 day-old normal mouse brain demonstrating the paucity
of white matter in the mouse brain. B, A magnetic resonance microscopy (MRM) image of the
cerebellum of a normal control C57BL/6J mouse brain. C, A magnetic resonance histology
(MRH) image of the cerebellum of a normal control C57BL/6J mouse brain. The qualitatively
different contrast allows us to unambiguously delineate the molecular layer of the cerebellum.
D, A Nissl-stained section of tissue through the cerebellum of a 100 day-old normal mouse.
E, An anatomical delineation derived from the Nissl-stained image highlighting the different
layers of the cerebellar cortex. Cerebellar white matter (cbw); granule cell layer of the
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cerebellar cortex (CBXg); molecular layer of the cerebellar cortex (CBXm); deep cerebellar
nuclei (DCN).
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Fig. 3. Gray Matter Atrophy in the Cerebella of Mice with EAE
A, Magnetic resonance microscopy image of the brain of a mouse with EAE with the
delineation of the cerebellum overlaid in yellow. B, Dot plot of the cerebellum (CB) volume
plotted against disease duration demonstrated an inverse correlation (R = −0.6178, n = 21, p
= 0.0028). The disease course for this cohort of mice is overlaid on the graph for illustrative
purposes. C, Magnetic resonance microscopy image of the brain of a mouse with EAE with
the delineation of the cerebellar white matter overlaid in yellow. D, Dot plot of the cerebellar
white matter (cbw) volume plotted against disease duration did not demonstrate a significant
correlation (R = −0.0747, n = 21, p = 0.75). The disease course for this cohort of mice is overlaid
on the graph for illustrative purposes. E, Magnetic resonance microscopy image of the brain
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of a mouse with EAE with the delineation of the cerebellar cortex overlaid in yellow. F, Dot
plot of the cerebellar cortex (CBX) volume plotted against disease duration demonstrated an
inverse correlation (R = −0.6207, n = 21, p = 0.0027). The disease course for this cohort of
mice is overlaid on the graph for illustrative purposes. G, Magnetic resonance histology image
of the brain of a mouse with EAE with the delineation of the molecular layer of the cerebellar
cortex overlaid in yellow. H, Dot plot of the molecular layer of the cerebellar cortex (CBXm)
volume plotted against disease duration demonstrated an inverse correlation (R = −0.6562, n
= 10, p = 0.039). The disease course for this cohort of mice is overlaid on the graph for
illustrative purposes.
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Fig. 4. Demyelination in the Cerebella of Mice with EAE
A, MBP immunostained confocal image at 10X magnification in the cerebellum of a normal
control mouse. B, MBP (red)/NF200 (green) double-stained confocal image at 60X
magnification demonstrating normal morphology in the cerebellar white matter. C, MBP/
NF200 double-stained confocal image at 60X magnification demonstrating normal
morphology in the granule cell layer of the cerebellar cortex. D, MBP stained confocal image
at 10X magnification in the cerebellum of a mouse with EAE (day 63). E, MBP/NF200 double-
stained confocal image at 60X magnification demonstrating a lesion devoid of myelin or axons
in the cerebellar white matter. F, MBP/NF200 double-stained confocal image at 60X
magnification demonstrating swollen axons and axon retraction bulbs in the granule cell layer
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of the cerebellar cortex (arrowheads). G, Dot plot of the molecular layer of the cerebellar cortex
(CBXm) volume plotted against MBP staining density in the cerebellar white matter
demonstrated a direct correlation (R = 0.6132, n = 12, p = 0.03398). H, Dot plot of the molecular
layer of the cerebellar cortex (CBXm) volume plotted against MBP staining density in the
cerebellar cortex demonstrated a direct positive correlation (R = 0.8069, n = 12, p = 0.001514).
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Fig. 5. Inflammation in the Cerebella of Mice with EAE
A, CD45 (red)/parvalbumin (green) double-stained confocal image at 10X magnification in
the cerebellum of a normal control mouse. B, CD45 immunostained confocal image at 63X
magnification demonstrating minimal CD45 staining in the cerebellar white matter (green
channel removed for clarity). C, CD45 immunostained confocal image at 63X magnification
demonstrating a minimal CD45 staining in the molecular layer of the cerebellar cortex (green
channel removed for clarity). D, CD45/parvalbumin double-stained confocal image at 10X
magnification in the cerebellum of a mouse with EAE (day 70). E, CD45 immunostained
confocal image at 63X magnification demonstrating a CD45+ cell with a macrophage-like
morphology in the cerebellar white matter (arrowhead) (green channel removed for clarity).
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F, CD45 immunostained confocal image at 63X magnification demonstrating a CD45+ cell
with a microglia-like morphology in the molecular layer of the cerebellar cortex (arrowhead)
(green channel removed for clarity). G, Dot plot of the molecular layer of the cerebellar cortex
(CBXm) volume plotted against CD45 staining density in the cerebellar white matter
demonstrated an inverse correlation (R = −0.6942, n = 12, p = 0.01226). H, Dot plot of the
molecular layer of the cerebellar cortex volume plotted against CD45 staining density in the
cerebellar cortex demonstrated an inverse correlation that did not reach statistical significance
(R = −0.5345, n = 12, p = 0.07338).
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Fig. 6. Characterization of CD45+ cells in the Cerebella of Mice with EAE
A, CD3 (red)/NF200 (green)/CD45 (blue) triple-stained confocal image at 40X magnification
focusing on a lesion near a blood vessel in the white matter of the cerebellum of a mouse with
EAE (day 55). B, CD3 (red)/NF200 (green) double-stained confocal image at 40X
magnification focusing on cellular infiltration in the granule cell layer of the cerebellar cortex
of a mouse with EAE (day 55). C, Mac-3 (red)/NF200 (green)/CD45 (blue) triple-stained
confocal image at 40X magnification focusing on a lesion near a blood vessel in the white
matter of the cerebellum of a mouse with EAE (day 55). D, Mac-3 (red)/NF200 (green) double-
stained confocal image at 40X magnification focusing on cellular infiltration in the cerebellar
cortex of a mouse with EAE (day 55). Dashed lines indicate the layers of the cerebellar cortex.
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Granule cell layer of the cerebellar cortex (CBXg); molecular layer of the cerebellar cortex
(CBXm); Purkinje cell layer of the cerebellar cortex (CBXp).
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Fig. 7. Apoptosis in the Cerebella of Mice with EAE
A, Caspase-3 immunostained light microscopy images at 10X magnification in the cerebellum
of a normal control mouse. B, Caspase-3 immunostained light microscopy images at 40X
magnification demonstrating minimal caspase-3 staining. C, Caspase-3 (black)/calbindin-2
(red) double-stained light microscopy images at 40X magnification demonstrating normal
morphology in the cerebellar cortex. D, Caspase-3 immunostained light microscopy images at
10X magnification in the cerebellum of a mouse with EAE (day 63). E, Caspase-3
immunostained light microscopy images at 40X magnification demonstrating caspase-3+ cells
with Purkinje cell-like morphology in the Purkinje layer of the cerebellar cortex. F, Caspase-3/
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calbindin-2 double-stained light microscopy images at 40X magnification demonstrating
calbindin-2+ Purkinje cells undergoing caspase-3 mediated apoptosis.
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Fig. 8. Purkinje Cells in the Cerebella of Mice with EAE
A, Calbindin-2 stained confocal images at 10X magnification in the cerebellum of a normal
control mouse. B, Calbindin-2 immunostained confocal images at 40X magnification
demonstrating normal morphology in the Purkinje layer of the cerebellar cortex. C, Calbindin-2
stained confocal images at 10X magnification in the cerebellum of a mouse with EAE (day
70). D, Calbindin-2 immunostained images at 40X magnification demonstrating a decrease in
Purkinje cell number, changes in their dendritic arborization, and a general loss in the
organization of the Purkinje layer of the cerebellar cortex. E, Dot plot of the molecular layer
of the cerebellar cortex volume (CBXm) plotted against the number of calbindin-2+ Purkinje
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cells demonstrated a direct correlation (R = 0.6287, n = 11, p = 0.03826). Cell counts for this
study focused on lobule I/II and III.
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Fig. 9. Synapsin is Decreased in the Cerebella of Mice with EAE
A, Synapsin stained confocal image at 40X magnification of the of the cerebellar cortex of a
normal control mouse. B, Synapsin stained confocal image at 40X magnification of the
cerebellar cortex of a mouse with EAE (day 55). C, Calbindin-2 stained confocal image at 40X
magnification of the cerebellar cortex of a normal control mouse. D, Calbindin-2 stained
confocal image at 40X magnification of the cerebellar cortex of a mouse with EAE (day 55).
E, Merge of synapsin (red)/calbindin-2 (green) double-stained confocal image at 40X
magnification of the cerebellar cortex of a normal control mouse. F, Merge of synapsin/
calbindin-2 double-stained confocal image at 40X magnification of the cerebellar cortex of a
mouse with EAE (day 55).
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Fig. 10. Time Course of Pathology in the Cerebella of Mice with EAE
A, Mean values and SEM of white matter CD45 staining density for control or EAE mice at
each time point. B, Mean values and SEM of gray matter CD45 staining density for control or
EAE mice at each time point. C, Mean values and SEM of white matter myelin basic protein
staining density for control or EAE mice at each time point. D, Mean values and SEM of gray
matter myelin basic protein staining density for control or EAE mice at each time point. E,
Mean values and SEM of Purkinje cell number for control or EAE mice at each time point.
Cell counts for this study focused on lobule I/II. The letter E indicates mice with EAE and the
letter N indicates normal, age-matched controls. The number following the letter indicates the
number of days post-induction. Asterisks indicate significance (* p < 0.05, ** p < 0.01, *** p
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< 0.005). All differences which are significant at p > 0.01 (two asterisks or more) survive the
application of the Bonferroni correction for post hoc testing.
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